Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 47
Filtrar
1.
Ter Arkh ; 89(3): 94-107, 2017.
Artigo em Russo | MEDLINE | ID: mdl-28378737

RESUMO

The paper presents the All-Russian consensus on the diagnosis and treatment of celiac disease in children and adults, which has been elaborated by leading experts, such as gastroenterologists and pediatricians of Russia on the basis of the existing Russian and international guidelines. The consensus approved at the 42nd Annual Scientific Session of the Central Research Institute of Gastroenterology on Principles of Evidence-Based Medicine into Clinical Practice (March 2-3, 2016). The consensus is intended for practitioners engaged in the management and treatment of patients with celiac disease. Evidence for the main provisions of the consensus was sought in electronic databases. In making recommendations, the main source was the publications included in the Cochrane Library, EMBASE, MEDLINE, and PubMed. The search depth was 10 years. Recommendations in the preliminary version were reviewed by independent experts. Voting was done by the Delphic polling system.


Assuntos
Doença Celíaca , Gerenciamento Clínico , Adulto , Doença Celíaca/classificação , Doença Celíaca/diagnóstico , Doença Celíaca/terapia , Criança , Medicina Baseada em Evidências , Humanos , Federação Russa
2.
Eksp Klin Gastroenterol ; (2): 32-5, 2014.
Artigo em Russo | MEDLINE | ID: mdl-25518472

RESUMO

The article describes the diffuse esophageal spasm which is not amenable to conservative treatment.


Assuntos
Espasmo Esofágico Difuso/diagnóstico , Espasmo Esofágico Difuso/parasitologia , Espasmo Esofágico Difuso/terapia , Adulto , Humanos
3.
Eksp Klin Gastroenterol ; (8): 60-5, 2014.
Artigo em Russo | MEDLINE | ID: mdl-25911914

RESUMO

The complex determination of serum autoantibodies to hepatic antigens using enzyme immunoassay and immunoblot allows to increase the frequency of overlap syndrome identification during autoimmune hepatic disorders and its early diagnostics, that has a big clinical, diagnostic and prognostic importance. The levels of overlap autoantibodies combine with biochemical index and with disease activity and intensity of autoimmune processes during overlap syndrome of primary biliary cirrhosis/autoimmune hepatitis (PBC/AIH).


Assuntos
Autoanticorpos/sangue , Autoantígenos/imunologia , Hepatite Autoimune/diagnóstico , Cirrose Hepática Biliar/diagnóstico , Fígado/imunologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Hepatite Autoimune/imunologia , Humanos , Cirrose Hepática Biliar/imunologia , Testes de Função Hepática , Masculino , Pessoa de Meia-Idade , Síndrome , Adulto Jovem
7.
Eksp Klin Gastroenterol ; (8): 11-6, 2013.
Artigo em Russo | MEDLINE | ID: mdl-24933942

RESUMO

Among the chronic diseases of the gastrointestinal tract of the special place occupied by inflammatory bowel disease (IBD), in which the lining of the intestine produces a significant number of neutrophils, which has prompted researchers and clinicians use a protein derived from neutrophils as a biomarker for the assessment of the intestinal wall and the effectiveness of treatment in patients IBD. One of these proteins is calprotectin (CP), which can be considered as a biomarker of activation, destruction and loss of neutrophil cells, to a lesser extent-- the activated monocytes and macrophages. Various studies have shown that the concentration of fecal calprotectin (FCP) correlates well with endoscopic and histological parameters of intestinal inflammation. Test the FCP can be used in healthy first-degree relatives of patients with IBD to assess the possible presence of subclinical variant of intestinal inflammation in this population. Thus, a simple test of the FCP can reduce the needs of various expensive and invasive method, including costs associated with them, especially in younger patients, where in terms of differential diagnosis of IBD is often not included neoplasia of the intestine. FCP is a non-invasive, inexpensive and at the same time, highly sensitive and specific biomarker that can be used successfully in the diagnosis, evaluation of the efficacy of treatment and predicting recurrence.


Assuntos
Fezes , Doenças Inflamatórias Intestinais/metabolismo , Complexo Antígeno L1 Leucocitário/metabolismo , Biomarcadores/metabolismo , Humanos , Inflamação/metabolismo , Neutrófilos/metabolismo , Valor Preditivo dos Testes
8.
Eksp Klin Gastroenterol ; (8): 45-9, 2013.
Artigo em Russo | MEDLINE | ID: mdl-24933948

RESUMO

Among 106 patients with autoimmune liver disease in 12 (11.3%) were found autoantibodies to asialoglycoprotein receptor (anti-ASGPR): in 5 (9.1%) of 55 with PBC, and 4 (17.4%) of 23 with AIH and 3 (10.7%) of 28 patients with syndrome chiasm (PBC + AIH). Detection of antibodies against the ASGPR is an effective method for diagnosis of autoimmune hepatitis. Further improvement of this method allows for monitoring and disease. Anti-ASGPR levels correlate with biochemical parameters and with the severity and manifestation autoimmune processes in patients with autoimmune hepatitis.


Assuntos
Receptor de Asialoglicoproteína/imunologia , Autoanticorpos , Hepatite Autoimune , Adulto , Idoso , Idoso de 80 Anos ou mais , Autoanticorpos/sangue , Autoanticorpos/imunologia , Feminino , Hepatite Autoimune/sangue , Hepatite Autoimune/diagnóstico , Hepatite Autoimune/imunologia , Humanos , Masculino , Pessoa de Meia-Idade
10.
Eksp Klin Gastroenterol ; (6): 35-8, 2013.
Artigo em Russo | MEDLINE | ID: mdl-24772858

RESUMO

At IBD in the exacerbation phase was detected the increase of fecal calprotectin (FC) level in 98% of patients. With increasing of clinical disease activity in patients with UC as well as CD was marked a significantly increased content of calprotectin in stool samples, which was accompanied by increase of indicators of inflammation acute phase: rising RRF, leukocytosis, an increase of frequency of stool with blood and mucus, fever and abdominal pain. In the phase of exacerbation the increase in concentration of CRP depends on the degree of inflammatory activity, rather than on lesion localization. The highest concentration of CRP was revealed at a high degree of IBD activity with stool frequency up to 8-10 times/day with impurity of blood and abdominal pain. At moderate activity of IBD, it is less expressed diarrhea (stool frequency 2-3 times a day), without blood, detected lower lever of PCF concentration--from 250 to 380 ug/g. A study of calprotectin concentrations in stool samples is considered to be reliable and sensitive method for evaluation of inflammatory activity in patients with inflammatory bowel disease.


Assuntos
Colite Ulcerativa/diagnóstico , Colite Ulcerativa/imunologia , Doença de Crohn/diagnóstico , Doença de Crohn/imunologia , Fezes/química , Complexo Antígeno L1 Leucocitário/análise , Adolescente , Adulto , Idoso , Biomarcadores/análise , Feminino , Humanos , Técnicas Imunoenzimáticas , Masculino , Pessoa de Meia-Idade , Índice de Gravidade de Doença , Adulto Jovem
11.
Eksp Klin Gastroenterol ; (3): 40-6, 2012.
Artigo em Russo | MEDLINE | ID: mdl-22830223

RESUMO

UNLABELLED: Detection of IgM and IgG Chlamydia and Mycoplasma pneumoniae indicates an aggravation of intracellular infections, including, possibly, due to immunosuppressive therapy. It is possible that the intracellular infection may mediate the occurrence of certain extraintestinal manifestations of inflammatory bowel disease (IBD), such as bronchitis, pneumonia, etc. Chronic persistent chlamydial and mycoplasmal infections lead to disruption of both cellular and humoral immunity, resulting in the formation of autoimmune processes in patients with IBD, and in the future--reduce the immune status against the immunosuppressive therapy. Detection of antibodies to Chlamydia and Mycoplasma pneumoniae accompanies with increased total immunoglobulin IgM, IgG in blood serum. Determining the level of proinflammatory and antiinflammatory cytokines in the acute stage of the disease allows to evaluate the activity of the inflammatory process and the nature of the immune response to intracellular infection. THE CONCLUSION: to prevent extraintestinal septic complications in patients with IgM antibodies to Chlamydia and Mycoplasma pneumoniae, is recommended to combine the long-term immunosuppressive therapy of IBD with antibiotic therapy, usually with macrolides.


Assuntos
Anti-Inflamatórios/efeitos adversos , Anticorpos Antibacterianos/sangue , Chlamydophila pneumoniae/isolamento & purificação , Imunossupressores/efeitos adversos , Doenças Inflamatórias Intestinais/terapia , Transplante de Células-Tronco Mesenquimais , Mycoplasma pneumoniae/isolamento & purificação , Adolescente , Adulto , Ácido Aminossalicílico/administração & dosagem , Ácido Aminossalicílico/uso terapêutico , Anti-Inflamatórios/administração & dosagem , Anti-Inflamatórios/uso terapêutico , Anticorpos Monoclonais/administração & dosagem , Anticorpos Monoclonais/uso terapêutico , Azatioprina/administração & dosagem , Azatioprina/uso terapêutico , Doença Crônica , Terapia Combinada , Citocinas/sangue , Quimioterapia Combinada , Feminino , Glucocorticoides/administração & dosagem , Glucocorticoides/uso terapêutico , Humanos , Imunidade Celular/efeitos dos fármacos , Imunidade Humoral/efeitos dos fármacos , Imunoglobulina G/sangue , Imunoglobulina M/sangue , Imunossupressores/administração & dosagem , Imunossupressores/uso terapêutico , Doenças Inflamatórias Intestinais/imunologia , Doenças Inflamatórias Intestinais/microbiologia , Infliximab , Masculino , Pessoa de Meia-Idade , Adulto Jovem
12.
Eksp Klin Gastroenterol ; (3): 47-58, 2012.
Artigo em Russo | MEDLINE | ID: mdl-22830224

RESUMO

Chronic inflammation in IBD is accompanied by an imbalance in the production of Tx1 and Tx2 cytokines. Imbalance of cytokine profile is important pathogenetic importance in chronic inflammatory process, since the formation of defective immune response to pathogenic agent promotes recurrence of the disease. Analysis of the dynamics of proinflammatory cytokines allows both the activity of inflammatory process and effectiveness. Increased levels of proinflammatory cytokines: TNF-alpha, IFN-gamma, IL-2, IL-5, IL-8, IL-12, IL-15 in serum of patients with IBD, indicate their possible involvement in the mechanisms of development of CD and UC. Increasing content of these cytokines is accompanied by increased activity of disease, which can be used in diagnose IBD activity.


Assuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Citocinas/sangue , Imunossupressores/uso terapêutico , Doenças Inflamatórias Intestinais/terapia , Transplante de Células-Tronco Mesenquimais , Adolescente , Adulto , Idoso , Ácido Aminossalicílico/administração & dosagem , Ácido Aminossalicílico/uso terapêutico , Anti-Inflamatórios não Esteroides/administração & dosagem , Anticorpos Monoclonais/administração & dosagem , Anticorpos Monoclonais/uso terapêutico , Azatioprina/administração & dosagem , Azatioprina/uso terapêutico , Terapia Combinada , Quimioterapia Combinada , Feminino , Glucocorticoides/administração & dosagem , Glucocorticoides/uso terapêutico , Humanos , Imunossupressores/administração & dosagem , Doenças Inflamatórias Intestinais/sangue , Doenças Inflamatórias Intestinais/imunologia , Infliximab , Cinética , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento , Adulto Jovem
13.
Eksp Klin Gastroenterol ; (2): 76-87, 2012.
Artigo em Russo | MEDLINE | ID: mdl-22808797

RESUMO

Chronic inflammation in IBD is accompanied by an imbalance in the production of TX1 and Th2 cytokines. Imbalance of cytokine profile is important pathogenetic value at chronic inflammatory process, since the formation of a defective immune response to pathogenic agent promotes recurrence of the disease. Analysis of the dynamics of proinflammatory cytokines allows to estimate the activity of the inflammatory process, and effectiveness of the therapy. Increased levels of proinflammatory cytokines: TNF-alpha, IFN-gamma, IL-2, IL-5, IL-8, IL-12, IL-15 in serum of patients with IBD, indicating their possible involvement in the mechanisms of development of CD and UC. The increase in the content of these cytokines was accompanied by increased activity of disease that can be used to diagnose IBD activity.


Assuntos
Anti-Inflamatórios/uso terapêutico , Anticorpos Monoclonais/uso terapêutico , Citocinas/sangue , Doenças Inflamatórias Intestinais/imunologia , Doenças Inflamatórias Intestinais/terapia , Transplante de Células-Tronco Mesenquimais , Adolescente , Adulto , Idoso , Anti-Inflamatórios/administração & dosagem , Anticorpos Monoclonais/administração & dosagem , Feminino , Humanos , Doenças Inflamatórias Intestinais/sangue , Doenças Inflamatórias Intestinais/tratamento farmacológico , Infliximab , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento , Adulto Jovem
15.
Eksp Klin Gastroenterol ; (6): 107-14, 2012.
Artigo em Russo | MEDLINE | ID: mdl-23402200

RESUMO

The article provides a brief overview of recent data on non-Hodgkin's lymphoma. We describe a special case primary isolation non-Hodgkin's lymphoma of the liver in a patient with chronic hepatitis C. Were analyzed medical errors at all stages of inspection and treatment of the patient. This exceptional case supplements small number of publications on a problem of the isolated lymphoma of a liver. We also wanted to pay attention once again to need of lifetime morphological research of a liver.


Assuntos
Hepatite C Crônica/diagnóstico , Hepatite C Crônica/terapia , Neoplasias Hepáticas/diagnóstico , Neoplasias Hepáticas/terapia , Linfoma não Hodgkin/diagnóstico , Linfoma não Hodgkin/terapia , Erros de Diagnóstico , Hepatite C Crônica/complicações , Hepatite C Crônica/patologia , Humanos , Fígado/patologia , Neoplasias Hepáticas/complicações , Neoplasias Hepáticas/patologia , Linfoma não Hodgkin/complicações , Linfoma não Hodgkin/patologia , Pessoa de Meia-Idade
17.
Eksp Klin Gastroenterol ; (5): 3-7, 2011.
Artigo em Russo | MEDLINE | ID: mdl-21919238

RESUMO

The article stresses that among the chronic diseases of the digestive tract occupy a special place inflammatory bowel disease (IBD)--UC and BC with multiple complications and the onset of early disability of patients. IBD is a serious issue of gastroenterology, since their etiology remains unknown, and specific treatment hasn't yet been developed. Finally, the prevalence and social significance of IBD also occupy a leading place among the diseases of the digestive organs, since they are characterized by recurrent course and have adverse medical and social prognosis. According to sources in various countries annually spend huge money for treatment of IBD. The costs of IBD depends on the severity and nature of complications, duration of illness, the choice of treatment, frequency of hospitalization and the patient's country of residence. Various studies demonstrate the feasibility of using more modern efficient methods of treatment (MSSC + therapy) to reduce the incidence of complications associated with IBD, resulting in huge costs.


Assuntos
Colite Ulcerativa/terapia , Doença de Crohn/terapia , Custos de Cuidados de Saúde , Transplante de Células-Tronco Mesenquimais , Adulto , Ácidos Aminossalicílicos/administração & dosagem , Ácidos Aminossalicílicos/economia , Ácidos Aminossalicílicos/uso terapêutico , Anti-Inflamatórios não Esteroides/administração & dosagem , Anti-Inflamatórios não Esteroides/economia , Anti-Inflamatórios não Esteroides/uso terapêutico , Colite Ulcerativa/economia , Colite Ulcerativa/patologia , Doença de Crohn/economia , Doença de Crohn/patologia , Feminino , Humanos , Masculino , Transplante de Células-Tronco Mesenquimais/economia , Pessoa de Meia-Idade , Recidiva , Resultado do Tratamento , Adulto Jovem
19.
Eksp Klin Gastroenterol ; (2): 31-6, 2011.
Artigo em Russo | MEDLINE | ID: mdl-21560640

RESUMO

The pathogenesis of atherosclerosis has been studied for over a hundred years, but so far no consensus on this issue doesn't exist. During this time, experts have gone from ideas of atherogenesis as a consequence of excess cholesterol in the diet to complex theories of the pathogenesis of atherosclerosis. Today generally accepted that one of the major risk factor for cardiovascular disease and atherosclerosis is dyslipidemia. When atherogenic dyslipidemia occur expressed disbiotic changes intestine and lead to endotoxemia, bacterial translocation and impaired liver function. The undoubted fact is that the liver plays an important role in the development of atherogenic dyslipidemia, and also is the target organ, which leads to the development of nonalcoholic fatty liver disease (NAFLD). Currently, NAFLD is a major risk factor for cardiovascular disease, it limits the possibility of adequate lipid-lowering therapy, increasing cardiovascular risk. Therefore, in the treatment of atherogenic dyslipidemia with statins and fibrates useful purpose hepatoprotectors. Choosing hepatoprotectors depends on the stage NAFLD.


Assuntos
Aterosclerose/etiologia , Dislipidemias/complicações , Fígado Gorduroso/complicações , Hipolipemiantes/uso terapêutico , Aterosclerose/prevenção & controle , Dislipidemias/tratamento farmacológico , Fígado Gorduroso/tratamento farmacológico , Ácidos Fíbricos/administração & dosagem , Ácidos Fíbricos/uso terapêutico , Humanos , Inibidores de Hidroximetilglutaril-CoA Redutases/administração & dosagem , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Hipolipemiantes/administração & dosagem , Testes de Função Hepática
20.
Eksp Klin Gastroenterol ; (2): 97-105, 2011.
Artigo em Russo | MEDLINE | ID: mdl-21560648

RESUMO

The article provides data of the pharmacoeconomic analysis (cost/effectiveness) of treatment of peptic ulcer, ulcerative colitis, Crohn's disease, gastroesophageal reflux disease, biliary sludge and cholelithiasis. It was shown that the most appropriate treatment scheme is one that characterized by lower costs per unit of effectiveness. Analysis of cost/effectiveness can give an economic assessment of clinical efficacy, compare alternative treatments and help to choose the method by which the efficiency increases faster than the level of costs.


Assuntos
Doenças do Sistema Digestório/economia , Doenças do Sistema Digestório/terapia , Farmacoeconomia , Custos de Cuidados de Saúde , Análise Custo-Benefício , Doenças do Sistema Digestório/tratamento farmacológico , Custos de Cuidados de Saúde/tendências , Humanos , Federação Russa
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA